Stimulant plus non-stimulant, guanfacine extended release (GXR)	Stimulant 	QALYs (Quality Adjusted Life Year) including impact of AEs	29696	29847	The combination therapy also increased QALYs by 0.028 (0.655 vs 0.627). Excluding the impact of AEs led to a QALY difference of 0.031 (0.660 vs 0.629).
Stimulant plus non-stimulant, guanfacine extended release (GXR) 	Stimulant	drug cost	2380	2515	adding GXR to existing stimulant monotherapy was associated with an incremental drug cost of $US1016 but a lower medical cost of $US124
Stimulant plus non-stimulant, guanfacine extended release (GXR) 	Stimulant	QALYs (Quality Adjusted Life Year) excluding impact of AEs	29696	29847	The combination therapy also increased QALYs by 0.028 (0.655 vs 0.627). Excluding the impact of AEs led to a QALY difference of 0.031 (0.660 vs 0.629).
Stimulant plus non-stimulant, guanfacine extended release (GXR) 	Stimulant	medical cost	2380	2515	adding GXR to existing stimulant monotherapy was associated with an incremental drug cost of $US1016 but a lower medical cost of $US124
Stimulant plus non-stimulant, guanfacine extended release (GXR) 	Stimulant	medical cost	2322	2575	Compared with maintaining existing stimulant monotherapy, adding GXR to existing stimulant monotherapy was associated with an incremental drug cost of $US1016 but a lower medical cost of $US124, resulting in a total incremental cost of $US892 at 1 year.
Stimulant plus non-stimulant, guanfacine extended release (GXR) 	Stimulant	QALYs (Quality Adjusted Life Year) excluding impact of AEs	29768	29847	Excluding the impact of AEs led to a QALY difference of 0.031 (0.660 vs 0.629).
Stimulant plus non-stimulant, guanfacine extended release (GXR)	Stimulant 	QALYs (Quality Adjusted Life Year) including impact of AEs	29696	29766	The combination therapy also increased QALYs by 0.028 (0.655 vs 0.627)
